Skip to Primary Navigation

Skip to main content

Fujifilm blazes a trail through pharma’s ethical quagmire

Clinician wearing personal protective equipment while injecting something into an egg.
Photo: Smith Collection/Gado/Getty Images

Kevin Kinsella

2 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

As advancements in research and drug development become more complex, bioethicists are helping companies find their footing along an increasingly ambiguous path.

The pharmaceutical industry resides on a terrain riddled with ethical landmines across research, product development, AI-enabled technologies, manufacturing, and commercialization over which pharma, biotech, and other life sciences companies must tread lightly. 

Fujifilm Holdings America Corporation recognized it was no exception and decided to take a proactive

, , , , ,

Get full access, free for a month

Start your 28-day free trial to continue reading and access
all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience